Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111995
Status:
COMPLETED
Last Update Posted:
2008-08-08
First Post:
2005-05-27
Brief Title:
Evaluating Aranesp for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure CRF Receiving Hemodialysis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-Blind Study Comparing Aranesp Darbepoetin Alfa and Recombinant Human Erythropoietin rHuEPO in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure CRF Receiving Hemodialysis
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the hemoglobin response to Aranesp darbepoetin alfa in black subjects African-Americans with chronic renal failure CRF receiving hemodialysis and to examine the safety profile
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None